Safety, Tolerability and Pharmacodynamics of BI 770371 Administered Intravenously in Patients With Compensated Cirrhosis Due to MASH: a Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled Trial
Latest Information Update: 03 Jul 2025
At a glance
- Drugs BI 770371 (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions
Most Recent Events
- 30 Jan 2025 Status changed from not yet recruiting to recruiting.
- 14 Jan 2025 Planned initiation date changed from 16 Dec 2024 to 15 Jan 2025.
- 19 Dec 2024 Planned initiation date changed from 25 Nov 2024 to 16 Dec 2024.